Clinical impact of drug coated balloon-based percutaneous coronary intervention in patients with multivessel coronary artery disease
Significantly lower MACE rate in patients treated with SeQuent® Please (NEO) compared to DES Shin ES et al. JACC Cardiovasc Interv. 2023;16(3):292-299
Overview
Observational registry:
DCB (study device = SeQuent Please® (NEO)) in patients with MVD (2 or more coronary lesions)
Propensity score matched to patients receiving DES
Primary endpoint:
MACE @24 months (cardiac death, MI, TVR, stroke, stent thrombosis and major bleeding)
Results
In DCB-group 34.3 % of patients were treated with DCB-only, 65.7 % with hybrid PCI (DES+DCB)
Stent-length was significantly reduced by 63.7 % in DCB-group
MACE after 24 months was significantly lower in DCB-group vs. DES (3.9 % vs. 11 %; p=0.002)
Total population:
508 patients
DCB-Based
(n=254)
DES-only
(n=254)
p-value
Clinical endpoint after 24 months
MACE
3.9 % (10)
11.0 % (28)
0.002
Cardiac death
0.4 % (1)
2.4 % (6)
0.047
MI
0
1.2 % (3)
0.082
Stroke
0
0.4 % (1)
0.313
ST (definite/probable)
0
0.4 % (1)
0.333
TVR
3.1 % (8)
6.3 % (16)
0.095
Major bleeding
0.4 % (1)
2.8 % (7)
0.027
Conclusion
The DCB-based treatment approach showed a significantly reduced stent burden in multivessel PCI and this led to a significantly lower rate of MACE than the DES-only treatment.
